Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
With Northway Biotech's expertise in biologics manufacturing, Mallia aims to enter the multi-billion-dollar alopecia market by delivering a safe and effective topical sCD83 treatment designed to stimulate hair follicle formation and promote sustained hair growth.
ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth.
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing the Pichia pastoris expression system. This collaboration includes the development of analytical methods, technology scale-up, and the manufacturing of a cGMP Drug Substance.
Dr. Manfred Groeppel, co-founder and Managing Director of Mallia Therapeutics, said: "With this partnership, we are advancing the development of sCD83 to turn our research into a scalable treatment for patients."
"Interestingly, sCD83's mode of action induces both the formation of new hair follicles and thus hair growth, and has the potential to redefine treatment approaches for hormone-induced androgenetic alopecia as well as immune-mediated alopecia areata," emphasizes Prof. Dr. Alexander Steinkasserer, co-founder and Managing Director of Mallia. "By developing a robust production process, we are ensuring the quality required for future clinical as well as commercial applications."
Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, expressed, "We are excited to be working with Mallia on developing the manufacturing process of sCD83. Our priority is to ensure the highest manufacturing standards and maintain clear, open communication as we collaborate every step of the way."
"Mallia's team and their innovative solution make this project particularly appealing to us given its huge potential and the large need from people all over the world for treatment. The strong and transparent collaboration we have established allows us to support Mallia with confidence as we move forward together quickly,"added André Markmann, PhD, VP of Business Development at Northway Biotech.
About Mallia Therapeutics GmbH
Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. The Company was founded in 2023 in Erlangen, Germany, and is led by an experienced management team and worldwide leading experts in the field of CD83, with more than 60 CD83-related publications and 20 years of experience in the field.
With sCD83, a potential treatment for hair loss in preclinical development, Mallia aims to enter the multi-billion-dollar alopecia market and provide patients with a safe and effective topical treatment.
Connect with us on LinkedIn or find out more here: https://mallia-therapeutics.com/
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced and professional team executes projects at every stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's extensive expertise and vertically integrated service offering enable rapid execution of multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and operates locations in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA. For more information, please visit www.northwaybiotech.com.
Mallia Therapeutics Contact:
Mallia Therapeutics GmbH
info@mallia-therapeutics.com
International Media Contact:
MC Services AG
Dr. Regina Lutz / Katja Arnold
Tel.: +49 (0)89 210 228 0
E-Mail: mallia-therapeutics@mc-services.eu
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
View the original press release on ACCESS Newswire
Northway Biotech
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Unveils AI-Powered Smart Search2.6.2025 08:30:00 CEST | Press release
A Universal Search Experience That Brings Speed, Simplicity, and Context to Business Intelligence SAN FRANCISCO, CA / ACCESS Newswire / June 2, 2025 / GoodData, the AI-native analytics platform, today introduced AI Smart Search, an intelligent search experience designed to help users instantly locate analytics content across their workspace. Whether it's a dashboard, visualization, or saved insight, Smart Search eliminates the guesswork of navigation and puts the right information at your fingertips, within seconds. By combining modern UX patterns with AI-powered semantic understanding, this new feature brings the ease of consumer-grade search tools to enterprise analytics. From quick lookups to deep discovery, Smart Search is built to support everyone, from data-savvy professionals to analytics engineers, making it easier than ever to find, reuse, and explore what already exists in your analytics environment. Search Anything. Instantly. Intelligently. With a single keystroke, users ca
The Battery Show Europe 2025 Champions Deep-Dive Learning and Global Dialogues2.6.2025 04:00:00 CEST | Press release
STUTTGART, GERMANY / ACCESS Newswire / June 2, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany (ESG), the only place to meet the entire advanced battery, Hybrid/Electric Vehicle technology and energy storage supply chain under one roof, returns this week as the definitive education and networking platform for the advanced battery and electric vehicle sectors. As global markets evolve, this event delivers the insight and access industry professionals need to navigate new regulations, scale production and drive innovation across the value chain. At the core of the 2025 conference program are three focused education tracks and access to ESG that address the sector's most urgent challenges and opportunities; Advanced Battery Technologies explores the latest breakthroughs in cell chemistry, performance optimization and next-generation materials; Battery Production and Vehicle Integration tackles real-world is
Over 100 Elite Competitors to Vie for Global Titles in Four World Coffee Championships at World of Coffee Geneva2.6.2025 00:37:00 CEST | Press release
Additional Competitions Include Coffee Design Awards and Best New Product Awards GENEVA, SWITZERLAND / ACCESS Newswire / June 2, 2025 / The global coffee community will gather in Geneva, Switzerland, from June 26-28, 2025, for World of Coffee Geneva 2025, hosted by the Specialty Coffee Association (SCA) at the Palexpo Exhibition and Convention Center. This premier event will feature four prestigious international coffee competitions, bringing together over 100 of the world's top competitors to vie for global titles. In addition to the championships, the event will also present the Coffee Design Awards and Best New Product Awards, spotlighting design and innovation in the specialty coffee industry. The four World Coffee Championships, Include: World Latte Art Championship (WLAC) - This competition showcases baristas' creativity and precision as they craft visually stunning designs using milk and espresso. Competitors are judged on symmetry, contrast, and originality across multiple roun
GoodData Rolls Out AI Assistant: Embeddable Generative Analytics You Can Trust29.5.2025 08:30:00 CEST | Press release
Next-Gen Conversational Analytics Now Available, Secure, and Fully Embeddable SAN FRANCISCO, CA / ACCESS Newswire / May 29, 2025 / GoodData today announced the general availability of GoodData AI Assistant, a conversational analytics solution that transforms how business users engage with data. Built to scale, the AI Assistant enables users to ask questions in plain language and receive precise, governed insights right where decisions are made. As a flagship feature of the GoodData AI platform, the AI Assistant redefines how organizations unlock value from analytics. It blends the power of generative AI with semantic context and robust enterprise controls, making data exploration faster, smarter, and secure by design. Conversational Analytics at Enterprise Scale With the release of GoodData AI Assistant, organizations gain access to a conversational interface that brings AI-driven data exploration to every user, without compromising governance or performance. With the launch of AI Assi
Quasar Medical Will Acquire Nordson MEDICAL Design and Development Business in Galway, Ireland, and Tecate, Mexico29.5.2025 07:30:00 CEST | Press release
Quasar Grows Global Full-Lifecycle CDMO Platform; Nordson MEDICAL Sharpens Focus on Core Components Business SAINT PAUL, MINNESOTA / ACCESS Newswire / May 29, 2025 / Quasar Medical, a global leader in the manufacturing of interventional and complex minimally invasive devices, announced it has signed a definitive agreement with Nordson Corporation (NASDAQ:NDSN) to acquire its design and development contract manufacturing businesses in Galway, Ireland, and Tecate, Mexico. This will strengthen Quasar's global position as a full-service Contract Development and Manufacturing Organization (CDMO), offering end-to-end solutions from initial design to large-scale production. The deal is expected to close in the third quarter of calendar 2025. The Galway and Tecate facilities will be integrated into Quasar's expanding global platform, adding specialized expertise in complex balloon and catheter design, rapid prototyping, and cost-efficient device near-shore assembly. Both sites provide Quasar w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom